RXD:NYE-ProShares UltraShort Health Care (USD)

ETF | Trading--Inverse Equity |

Last Closing

USD 10.82

Change

+0.25 (+2.35)%

Market Cap

N/A

Volume

8.50K

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-02-14 )

Largest Industry Peers for Trading--Inverse Equity

Symbol Name Price(Change) Market Cap
SH ProShares Short S&P500

+0.03 (+0.07%)

USD 1.02B
SOXS Direxion Daily Semiconductor B..

+0.01 (+0.05%)

USD 0.61B
PSQ ProShares Short QQQ

-0.11 (-0.31%)

USD 0.55B
SPXU ProShares UltraPro Short S&P50..

+0.04 (+0.20%)

USD 0.51B
SDOW ProShares UltraPro Short Dow30

+0.46 (+1.04%)

USD 0.23B
YANG Direxion Daily FTSE China Bear..

-3.60 (-7.47%)

USD 0.22B
SPDN Direxion Daily S&P 500® Bear ..

+0.02 (+0.14%)

USD 0.15B
FNGD MicroSectors FANG+ Index -3X I..

-0.16 (-1.45%)

USD 0.14B
RWM ProShares Short Russell2000

+0.02 (+0.11%)

USD 0.14B
DOG ProShares Short Dow30

+0.10 (+0.39%)

USD 0.13B

ETFs Containing RXD

RLD:CA 0.00 % 0.61 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Trading--Inverse Equity) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -9.08% 47% F 8% B-
Dividend Return N/A N/A N/A N/A N/A
Total Return -9.08% 47% F 8% B-
Trailing 12 Months  
Capital Gain 2.14% 98% N/A 41% F
Dividend Return 3.94% 77% C+ 59% D-
Total Return 6.07% 98% N/A 39% F
Trailing 5 Years  
Capital Gain -66.83% 70% C- 6% D-
Dividend Return 2.79% 66% D+ 7% C-
Total Return -64.04% 69% C- 5% F
Average Annual (5 Year Horizon)  
Capital Gain 63.85% 40% F 95% A
Dividend Return 65.13% 40% F 95% A
Total Return 1.28% 60% D- 31% F
Risk Return Profile  
Volatility (Standard Deviation) 433.62% 62% D 3% F
Risk Adjusted Return 15.02% 49% F 31% F
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.